Evidence map›Paper›PMID 22311234›Full record

ArticleNeurocritical care2012

Treatment of intracerebral hemorrhage with tranexamic acid after thrombolysis with tissue plasminogen activator.

K F French, Jacob White, R E Hoesch

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Neurocritical care, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Benefits of the tranexamic acid in head trauma with no extracranial bleeding: a prospective follow-up of 180 patients.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2019
    Trial
  3. The effect of tranexamic acid in traumatic brain injury: A randomized controlled trial.Chinese journal of traumatology = Zhonghua chuang shang za zhi · 2017
    Trial
  4. Review
  5. Article
  6. Thrombolysis with Systemic Recombinant Tissue Plasminogen Activator in Children: A Multicenter Retrospective StudyTurkish journal of haematology : official journal of Turkish Society of Haematology · 2021
    Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Update on Neurocritical Care of Stroke.Current cardiology reports · 2017
    Review
  12. Therapies for Hemorrhagic Transformation in Acute Ischemic Stroke.Current treatment options in neurology · 2017
    Review
  13. Systemic Thrombolysis for Pulmonary Embolism: A Review.P & T : a peer-reviewed journal for formulary management · 2016
    Article
  14. Review
  15. Review
  16. Anticoagulation drug therapy: a review.The western journal of emergency medicine · 2015
    Review
  17. Review
  18. Review
  19. Fibrinogen Concentrate for the Treatment of Thrombolysis-Associated Hemorrhage in Adult Ischemic Stroke Patients.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

K F FrenchDepartment of Neurology, Clinical Neurosciences Center, University of Utah School of Medicine, 175 N Medical Drive East, Salt Lake City, UT, Utah 84132, USA. Kris.french@hsc.utah.edu
Jacob White
R E Hoesch
University of Utah · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThrombolytic treatment with intravenous tissue plasminogen activator (i.v. tPA) is the only FDA-approved therapy for acute ischemic stroke. There are risks associated with thrombolytics, including intracranial and extracranial hemorrhage and hypersensitivity reactions. Established treatment for post-tPA hemorrhage includes administration of blood products including cryoprecipitate, fresh frozen plasma, and platelets which have poorly established efficacy. Tranexamic acid (TXA) and epsilon-aminocaproic acid (EACA) have been studied as hemostatic therapies in post-operative hemorrhage, menorrhagia, intracranial hemorrhage (ICH), subarachnoid hemorrhage, and trauma patients. There is no reported literature on the use of TXA to reverse thrombolytic therapy with tPA.

methodsThis is a case report of a Jehovah's Witness patient who was unwilling to receive blood products after developing symptomatic ICH following i.v. tPA. He consequently received TXA for reversal of thrombolytic therapy.

resultsThe patient received a total of 1.675 g of i.v. TXA within 3 h of finishing the iv tPA. Repeat brain imaging with computed tomography and magnetic resonance imaging revealed no further expansion of hemorrhages.

conclusionTXA is an inexpensive medication which competitively inhibits the activation of plasminogen and can be given to reverse thrombolysis in the setting of hemorrhage after i.v. thrombolytic therapy.

Indexed as

Antifibrinolytic AgentsCerebral HemorrhageDrug InteractionsFatal OutcomeFibrinolytic AgentsHumansMaleMiddle AgedThrombolytic TherapyTissue Plasminogen ActivatorTranexamic AcidAntifibrinolytic AgentsFibrinolytic AgentsTissue Plasminogen ActivatorTranexamic Acid

Identifiers

PMID22311234
OpenAlexW2041657236

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.